Data Sheet (Cat.No.T70407)

TargetMol

cemadotin free base

Chemical Properties



CAS No. : 159776-69-9

Formula: C35H56N6O5

Molecular Weight: 640.86

Storage: Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Cemadotin free base(LU103793 free base) is a novel anti-limiting peptide , an analog of Dolastatin 15, a naturally occurring cytotoxic peptide that blocks mitosis and inhibits microtubules (tubulin) with a Ki of 1 μM. Cemadotin is used in research against cancer.
Targets(IC50)	Microtubule Associated
In vitro	Cemadotin (0-1 μM) significantly enhances the frequency of rescue while exerting minimal impact on the occurrence of catastrophes.[1] Cemadotin (0-100 μM ; 35 min) demonstrates a dose-dependent inhibition of polymerization in Tubulin-treated Strongylocentrotus purpuratus.[1] Cemadotin (0-1000 nM) selectively suppresses the rate and magnitude of tubulin growth excursions, with suppression correlating to drug concentration.[1] Cemadotin (400 pM~300 nM ; 72 h) inhibits the viability of HEK 293, F9, and HL60 cancer cells.[2]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5604 mL	7.802 mL	15.604 mL
5 mM	0.3121 mL	1.5604 mL	3.1208 mL
10 mM	0.156 mL	0.7802 mL	1.5604 mL
50 mM	0.0312 mL	0.156 mL	0.3121 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Jordan MA, et al. Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry. 1998 ; 37(50):17571-17578.
Bernardes GJ, et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl. 2012 ; 51(4):941-944.
Supko JG, et al. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemother Pharmacol. 2000 ; 46(4):319-328.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481